Company / Financials
Tandem Diabetes Care Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.0B
FY2025 · +7.9% YoY
Net Income
-$204.7M
FY2025 · -113.2% YoY
Profit Margin
-20.2%
FY2025 · net income / revenue
ROE
-131.9%
FY2025 · return on equity
Total Assets
$881.1M
FY2025
Total Debt
$310.0M
2.00x debt/equity
Equity
$155.2M
FY2025
ROA
-23.2%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.0B+7.9% YoYNet Income HistoryProfit after all expenses and taxes-$204.7M-113.2% YoYGross Profit HistoryRevenue minus cost of goods sold$546.0M+11.5% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$468.7M+4.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$187.3M-88.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$445.0M+14.2% YoYR&D Expense HistoryResearch and development spending$193.1M-2.9% YoYIncome Tax HistoryTotal income tax expense$4.4M+6.8% YoYEPS (Basic) HistoryBasic earnings per share-$3.43-133.3% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$3.43-133.3% YoY